Sirtex delivers mixed blessing

Sirtex has delivered a dividend well ahead of expectations, but at the stock's current price-earnings multiple it appears to be trading at a premium.

Liver cancer treatment developer Sirtex (SRX) has announced a better than expected dividend for the year, but that isn’t likely to quell concerns about its full valuation.

Sirtex will pay a final dividend of 12 cents a share for 2012-13 compared with consensus forecast of just 10.9 cents a share.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles